USPTO and WIPO Publish NimbuDerm, Patent Applications -- Important Milestones in Advancing Quick-Med's Global Intellectual Property

October 15, 2009

Quick-Med, a pioneer in advanced antimicrobial technologies for medical and consumer applications, announced today that USPTO and the World Intellectual Property Organization have published Company patent applications covering Disinfectant Alcohol-Soluble Quaternary Ammonium Polymers.

GAINESVILLE, FL, October 15, 2009 /24-7PressRelease/ -- Quick-Med Technologies, Inc. (OTCBB: QMDT), a pioneer in advanced antimicrobial technologies for medical and consumer applications, announced today that the United States Patent and Trademark Office and the World Intellectual Property Organization have published Company patent applications covering Disinfectant Alcohol-Soluble Quaternary Ammonium Polymers.

These patent applications, which have been assigned the United States Patent and Trademark Office Publication Number US2009/0246165 A1 and the International Publication Number WO 2009/089346 A3, disclose the innovative technology of a durable disinfectant that can be bonded to various surfaces. The technology was initially developed to provide highly effective, long-lasting protection on skin, thus overcoming a shortcoming common to most hand sanitizers. However, the applicability of the technology and the associated patent applications are very broad-based in terms of both product applications and the selection of material forms that it produces. The invention covered by this US patent application had previously been published by WIPO as WO2007/024973 A1.

"Quick-Med's NimbuDerm technology has the potential to dramatically change the hand-hygiene paradigm by combining the immediate disinfection power of an instant sanitizer with the long-lasting antimicrobial persistence of an advanced bio-active polymer," declared Dr. Jerry Olderman, Vice President of Research & Development. "With many infections being transferred via hand contact, we believe NimbuDerm's third-generation technology could bring a new level of hand-hygiene assurance to consumers and healthcare professionals alike," he observed.

Laboratory tests demonstrate that NimbuDerm's unique antimicrobial polymer properties will kill more than 99.99% of disease causing germs, including the lethal strain of MRSA. Human use tests show that NimbuDerm also provides the same high level of continuing antimicrobial protection for 6 hours after each application without wearing off or losing its effectiveness. Poor hand hygiene is considered to be a major contributor to the increase in MRSA infections. MRSA, which has been identified in hospitals for 4 decades, is now increasingly found in schools, gymnasiums, and offices, and on common touch surfaces such as keyboards, door knobs, desktops, telephones and shopping cart handles. MRSA is becoming increasingly problematic, not only in acute care settings, but also in long-term care facilities and the community.

The material which is both colorless and odorless can be produced in such forms as gels, films, fibers, foams, sealants, tubes, rods, sheets, powders and surface impregnations. Other product applications covered by the pending patents include a number of medical devices such as catheters, tubing and wound dressings. Also included are such applications as adhesives, hard surface protective coatings and human or animal skin sanitizers.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS and NimbuDerm applications in several advanced medical device formats including traditional and advanced wound care dressings, adhesives, medical grade thermoplastics, and skin sanitizers. NIMBUS is the FDA-cleared technology that is being marketed in a line of wound dressings. The company has also recently announced its Stay Fresh technology for apparel and other textile applications. For more information, see: http://www.quickmedtech.com.

CONTACT:
J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: lgreeno@quickmedtech.com

2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS is a registered trademark and NimbuDerm and Stay Fresh are trademarks of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at http://www.sec.gov.

---
Press release service and press release distribution provided by http://www.24-7pressrelease.com